Клиническая эффективность и безопасность Дорназы альфа в лечении хронического бронхолегочного процесса у детей, больных муковисцидозом
Диссертация
При применении Пульмозима у 29,7% детей выявлены побочные эффекты в первые 2 недели от начала терапии: фарингит — у 9,6%, ларингит — у 13,3%, ринорея — у 3,2%, гипертермия — у 1,6%, бронхоспазм — у 4,8% больных. Тем не менее, большинству этих больных Пульмозим не отменяли, т.к. у 70% из них побочное действие купировалось самостоятельно в течение 2 недель. Катамнестические клинические наблюдения… Читать ещё >
Список литературы
- Абилов Б.А. Клиническое значение структурно-функционального состояния цитомембран в жидкости бронхоальвеолярного лаважа при хронических бронхолегочных заболеваниях у детей. Автореферат дисс. канд. мед. Наук. — М. — 1991.
- Бабий ИЛ. Этапное лечение и некоторые вопросы патогенетической терапии муковисцидоза у детей. Автореферат дисс. док-pa мед. наук. -М. — 1989,-С.28.
- Вельтищев О.Е., Каганов С. Ю., Таль В. М. Врожденные и наследственные заболевания легких у детей. М. Медицина, 1986 -с.187−188
- Гришина Г. О., Ладодо К. С., Капранов Н. И. Роль диеты и заместительных ферментов в комплексной терапии больных муковисцидозом. // Тезисы международного симпозиума по детской гастроэнтерологии. Москва. 24−26 сентября 1990. — С.37.
- Гудзенко Ж.П., Безруков Л. А., Каминская Е. К. и др. К вопросу желудочно-кишечных проявлений при муковисцидозе// Мат. Х Всесоюзн. Съезда педиатров. -М., 1974. С. 299.
- Диагностика и лечение дислипидемий у детей: Метод, рекомендации / Ю. А. Князев. М., 1985. — С.37.
- Капранов Н.И. Современное состояние проблемы муковисцидоза в России // Материалы симпозиума «Муковисцидоз-96″. М., 1997. — С.4−12.
- Капранов Н.И. Физическое развитие детей, больных муковисцидозом \ Педиатрия. 1985. — № 4. — С. 45−46.
- Капранов Н.И., Каширская Н. Ю. Актуальные проблемы муковисцидоза на современном этапе // Пульмонология. 1997. — № 4. -С.7 -16.
- Капранов Н.И., Рачинский С. В. Муковисцидоз. М.:1995. — 187с.
- Капранов Н.И., Шабалова JI.A., Каширская Н. Ю., Воронкова А. Ю. и др. „Муковисцидоз“, методические рекомендации, Медпрактика-М, 2001, стр.12−59.
- Каширская Н.Ю., Туркина Т. И., Агейкин В. А. Характеристика эндо- и экзогенной функции поджелудочной железы и спектра липидов сыворотки крови у детей, больных муковисцидозом. // Педиатрия. -1989.-№ 12.- С.85−89.
- Каширская Н.Ю., Капранов Н. И. Методы исследования физического статуса детей.// Методические рекомедации.1999.
- Каширская Н.Ю., Капранов Н. И. Поражение органов пищеварения и их коррекция при муковисцидозе. // Русский медицинский журнал. -Том.5. N14, июль. — 1997. — С.892−898.
- Каширская Н.Ю., Капранов Н. И., Нетребенко O.K. Методы исследования физического статуса детей. М.: Компания Нестле. 1999. -с.24.
- Конференция по достижению консенсуса: практическое применение Пульмозима®-. Pediatric pulmonology 17: 404−408 (1994).
- Матина И.А., Неудахин Е. В., Капранов Н. И. и др. Легочное сердце у детей с муковисцидозом // Детская больница. 2000. — № 2. — С.32−35).
- Лайтинен А. Автономный контроль бронхиальной обструкции. Лечение различных видов астмы. М., 1988. — С.55−69.
- Орлов А.В., Желенина Л. А., Гембицкая Т. Е. и др. Этапное лечение реабилитация детей с муковисцидозом \ Педиатрия. 1994. — № 3. С.74−75.
- Павлов Г. В., Шилко В. И. Муковисцидоз от детского возраста до взрослого. Екатеринбург: Изд-во Урал, ин-та, 1992. — С. 144.
- Петрова Н.В. „Определение относительных частот некоторых мутаций гена CFTR и анализ гаплотипов сцепленных с ним ДНК-маркерных локусов в популяциях России.“ Автореферат дисс. канд. биол. наук, М., 1996, с. 6.
- Петрова Н.В., Гинтер Е. К. „Десятилетний опыт молекулярно-генетической диагностики муковисцидоза в МГНЦ РАМН“, Пульмонология, 2001, 3, 17−20.
- Постникова Л.Б., Гельтцер Б. И., Панфилов Д. Н. Мукоциллиарный клиренс у больных острой пневмонией. Пульмонология 1992. — № 4. Приложение. — С. 586.
- Рачинский С.В., Капранов Н. И., Торчинский М. Ю. Новое в изучении муковисцидоза \ Вопр. охраны материнства и детства. 1989. -Т. 34, № 11. — С.3−9.
- Рачинский С.В., Капранов Н. И., Турина Е. И. Прогноз муковисцидоза у детей \ Педиатрия. 1984. — С.21−22.
- Рачинский С.В., Таточенко В. К. Болезни органов дыхания у детей -М.:Медицина, 1987 с.425−426
- Сергеева Л.М. Клинико-лабораторная оценка муколитического эффекта Пульмозима у больных муковисцидозом. // Диссертация кандидата медицинских наук. Екатеринбург., 1999.
- Симонова О.И., Волкова Е. П., Капранов Н. И., Семыкин С. Ю., Передерко Л. В. Психологические особенности у детей с муковисцидозом. Детский доктор, 1999, № 5,с. 24−28.
- Федосеев Г. Б. Механизмы обструкции юронхов. -СПб.: Медицинское информационное агенство, 1995−336С.
- Хафизова З.А. Клинические особенности муковисцидоза в зависимости от генотипа: Автореф. дисс.. канд. мед. наук. -М. 1992. -С.21.
- Чучалин А.Г. Механизмы защиты органов дыхания. Пульмонология. 1992ю — № 1, Приложение. — С.8−15.
- Чучалин А.Г., Самильчук Е. И. Муковисцидоз состояние проблемы \ Терапевт, арх. — 1993. — Т.65., № 3. — С. 3−9.
- Шабалова Л.А., Семыкин С. Ю., Иванов В. А. и др. Опыт антибактериальной терапии муковисцидоза у детей // Международный медицинский журнал.-1998.-№ 11,12.-С. 986−999.
- Aaderson MP, Gregori RF, Thompson et al. Demonstration that CFTR is a chloride chanel by aiteration of its anion selectivity. Sciencel991: 253- 202−5.
- Aitken ML., Burke W., McDonald G et al. Recombinant human Dnase inhalation in normal subjekt and patients whit cystic fibrosis. Phase 1 study. J Am. Med Assoc 267: 1947−1951.
- Alton E.F., Gedders DM. Gene therapy for cystic fibrosis: a clinical perspective. Gene Ther 1995−2:88−95.
- Andersen. D.H. Cystic Fibrosis of the pancreas and its relation to celiac disease // Am. J. Dis. Child. 1938. — V.56. — P.344−399.
- Anderson G.P., Shinagawa K. Neutrophil elastase inhibitors as treatments for emphysema and chronic bronchitis. Current Opinion in Antiinflammatory and Immunomodulatory Investigational Drugs, 1999, Vol. 1, № 1, pp. 29−38.
- Arcasou S.V. Patogenesis of airway disease in cystic fibrosis. Abstracts of Current NIH Support Research Grants in CF. 1998 — Project Number: 51. F 32 HL 9 575−02.
- Balfour-Lynn, J.R.Soc.Med 1999, 92, Suppl 37, 29−30.
- Balough K., McCubbin M., Weinberger M., Smits W., Alirens R., and Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr. Pulmonol., 1995, Vol. 20, pp. 63−70.
- Bauer MI, McDougal J, Schumacher RA. Comparison of manual and mechanical chest percussion ia hospitalized patients with cystic fibrosis. J Pediatr 1994- 124: 250−4.
- Berger M, Sorensen RU, Tosi MF, Dearborn DG, Doring G. Complement receptor exspression on neutrophils at an inflammatory site the pseudomonas-infected lung in. cystic fibrosis J Clin Invest 1989- 84: 130 313.
- Berger M. Inflammation in the lung in cystic fibrosis. Clin. Rev. Allergy, 1991, Vol. 9, pp. 119−142.
- Birrer P., McElvaney N.G., Rudeberg G., Sommer C.W., Liechti-Gallati S., Kraemer R., Hubbard R., Crystal R.G. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am. J. Respir. Crit. Care Med., 1994, Vol. 150, pp. 207−213.
- Bruce M.C., Poncz L., Klinger J.D., Stern R.C., Tomashefski J.R. Jr., Dear-born D.G. Biochemical and pathological evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am. Rev. Respir. Dis., 1985, Vol. 132, P.529−535.
- Cheng S.H., Gregory J. et al. defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. // Cell. -1990. V.63. — P.827−834.
- Chrispin A.R., Norman A.P. The systematic evaluation of the chest radiograph in cystic fibrosis // Pediatr. Radiol. 1974. -V.2. — P.101−106.
- Collins F. Cystic Fibrosis: Molecular biology and therapeutic implications. // Science. 1992. — V.256. — H.774−779.
- Convay Steven P. Recombinant human DNase (rhDNase in cystic fibrosis: is it cost effective? Archives of Disease in Childhuud. 1997, Vol 77, N 1, p 1−3.
- Corey M.L. Longitudinal studies in cystic fibrosis // Proceedings of the 8th International congress of cystic fibrosis. Toronto, Canada, 1980. -P.246−255.
- Costello CM, O’Conner CM, Finlay GA, Shiels P, FitzGerald MX, Hayes JP. Effect of nebulised recombinant DNase on elastase load in cystic fibrosis. EurRespir J 1996- 9: 2193−2195.
- Davis P.B., Cystic fibrosis. N.Y.: Marcel Dekker, Inc., 1993.-551 P.
- Delaney S.L., Alton EWFW., Smith S.N. Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. //EMBO J 1996- 15: 955−63.
- Denning G.M., Anderson M.P., Amara J. F. Processing of mutant cystic fibrosis conductance regulator is temperature-sensitive. // Nature 1992- 358:761−4.
- Denning G.M., Ostedgaard M.G., Welsh M.J. Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epythelia. // J. Cell Bioll. 1992. — V.118. — P.551−559.
- Desai M, Weller PH, Spenser DA. Clinical benefit from nebulized human recombinant Dnase in Kartagener syndrom. Pediatr.Pulmonol. 1995, Vol. 20, N5, p.307−308.
- Di Sant Agnese P.A., Darling R.C., Perera G.A., Shea E. Abnormal electrolytes composition of sweat in cystic fibrosis of the pancreas. Clinical significance and relationship of the disease. // Pediatrics. 1953. — V.12. -P.549. .
- Di Sant Agnese P.A., Davis et al. Cystic fibrosis in adults. 75 cases in the reviewof 232 cases in the literature.// American Journal of Medicine 66. P.698−701.
- Dodge JA, Morison S, Levis PA et al. Cystic fibrosis in the United Kingdom, 1968−1988: incidence, population and survival. Pediatric and Perinatal Epidemiology 1993- 157−166.
- Dork Т., Macek M., Mekus F et al. Characterisation of a novel 21-kb deletion, CFTRdele2,3(21kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe // Hum. Genet. 2000. -Vol.106. -P.259−268.
- Edited by J.A.Dodge, D.J.H.Brock, J.H. Widdicombe. \ Cystic Fibrosis. Current Topics. Vol.2. \ - 1994. — P.327−342.
- Ellis L., Kalnins D., Corey M., Pencharz P., Durie P. Correlation between fecal weight, fecal fat and fecal energy in patient with cyctic fibrosis. Pediatr Pulmonol 1997.- Suppl.N.14: 307.
- Estivill X., Farral M., et al. Linkage diasequilibrum between cystic fibrosis and linked DNA polymorphism in Italian families. // Am. J. Hum. Genet. 1988. — v.43. — P.23−28.
- Fernando A. de Abreu e Silva, J.A.Dodge. Guidnes for the diagnosis and management of cystic fibrosis. WHO Human Genetics Programme and the International Cystic Fibrosis Association. 1996. — P. 1−28.
- FitzSimmons SC. The changing epidemiology of Cystic Fibrosis. // J. Pediatr. 1993. — V.122 — P.9.
- Frizzell R.A. Cystic fibrosis: a disease of ion channels. // JCNI. 1987. -V.IO.-P.190.
- Ghezzi P., Sacco S., Agnello D., Marullo A., Caselli G., Bertini R. LPS in-duces IL-6 in the brain and in serum largely through TNF production. -Cytokine 2000, Vol. 12, pp. 1205−1210.
- Gibson L.E., Cooke R.E. A test for concentrtion of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocrpine by iontophoresis. // Pediatrics. 1959. V.23. — P.545
- Goldman M.J., Anderson G. M., Stolzenberg E.D., Kari U.P., Zasloff M., and Wilson J.M. Human b-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell, 1997, Vol. 88, pp. 553−560.
- Goldstein W., Doring G. Lysosomal enzymes from polymorphonuclear leu-kocytes and proteinase inhibitors in patients with cystic fibrosis. Am. Rev. Respir. Dis., 1986, Vol. 134, pp. 49−56.
- Goodchild M.C., Dodge J.A. Cystic fibrosis. Manual of diagnosis and management. Bailliere Tindall. London, Philadelphia, Toronto. 1987.
- Guggino WB. Presented an the Tenth Annual North American Cystic Fibrosis Conference-October 24−27,1996- Orlando, Florida.
- Gurwitz D., CoreyM., Francis P.W.J., Crozier D., Levison H. Perspectives in cystic fibrosis. // Pediatr. Clin. N. Am. 1979. — V.26. -P.603−608.
- Hadjm В., Johansen P.G., Anderson C.M. Pancreozimin secretin test of exocrine pancreatic function in cystic fibrosis. // Can. Med. Assoc. J. 1968. -V.98. — P.377−385.
- Hodson M E, Shah P L. Dnase trials in cystic fibrosis. // Eur Resp J, 1995- 8: 1786−91.
- Hodson M., Geddes D. Cystic Fibrosis. // Chapman London — 1995. -P.439.
- Hodson M.E. Dornase in treatment of chronic bronchitis. Ann. Pharmacotherapy, 1996, Vol 30, N 6, p 674−675.
- Hubbard R.C., Crystal R.G. Strategies for aerosol therapy of alpha-1 antitrypsin deficiency by the aerosol route. Lung, 1990, Vol. 168 (Suppl I), pp. 565- 578.
- Huhn RD, Pennline K, Radwanski E, Clarke L, Sabo R, Cutler DL. Effects of single intravenous doses of recombinant human interleukin-10 on subsets of circulating leukocytes in humans. Immunopharmacology, 1999, Vol. 41, pp. 109−117.
- Janoff A., White R., Carp H., Harel S., Dearing R., Lee D. Lung injury in-duced by leukocytic protease. Am. J. Pathol., 1979, Vol. 97, pp. 111−129.
- Johnson D.A., Carter-Hamm В., Dralle W.M. Inactivation of human bronchial mucous proteinase inhibitor by Pseudomonas aerugenosa elastase. -Am. Rev. Respir. Dis., 1982, Vol. 126, pp.1070−1073.
- Kahn T.Z., Wagener J.S., Bost Т., Martinez J., Accurso F.J., Riches D.H.W. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med., 1995, Vol. 151, pp. 1075−1082.
- Kapcala L.P., Chautard Т., Eskay R.L. Effects of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infections, and inflammatory stress. Ann. N.Y. Acad. Sci., 1995, Vol. 771, pp. 419−437.
- Kelly D. Diseases of the liver and biliary system in children. -1998-P.141−149.
- Kerem BS., Rommens JM., Buchanan JA. et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989- 245: 1066−80.
- Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potencial difference techniques and protocol for assenssing eficracy of gene transfer in cystic fibrosis. Hum Gene Ther 1995−6:445−55.
- Koch C, Hoiby NS. Pathogenesis of cystic fibrosis. Lancet 1993- 341: 1065−9.
- Konstan M.W., and Berger M Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr. Pulmonol., 1997, Vol. 24, P. 137−142.
- Konstan MW, Byard PI, Hopel CL, Devis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. // N Engl J Med 1995- 332: 848 854.
- Konstan MW, Stern RC, Docrshuk CF. Efficacy of the flatter device for airway mucus clearance in patient with cystic fibrosis // J Pediatr 1994- 124: 689−93.
- Kopelman H.R., Durie P., Gaskin K.J., Weizman Z., Forstner G.G. Pancreatic fluid and protein hyperconcentration in cystic fibrosis. // N. Engl. J. Med. 1985. — V.312. — P.329−334.
- Lethem M.I., James S.L., Marrion С et al. The origin of DNA assotiated with mucus glycoproteins in cystic fibrosis sputum//Eur.Respir.J.-1990.-Vol.3-P. 19−23
- Liou TD, Adler FR, FitzSimmons SC, Cahill ВС, Hibbs JR, Marshall ВС. Predictive 5-Year Survivorship Model of Cystic Fibrosis. Am J Epidemiol Vol 153, N4, 2001, 349.
- Luder E., Kattan M., Tanzer-Torres G., et al. Current recomendations for breast-feeding in Cystic Fibrosis Centers. // Am. J. Dis. Child. 1990 -Vol.144 — P.1153−1156.
- Ma J., Tasch J.E., Tao Т., Zhao J., Xie J., Drumm M.L., Davis P.B. Phosphorylation-dependent block of cystic fibrosis transmem-brane conductance regulator chloride channel by exogenous R domain protein. J. Biol. Chem., 1996, Vol. 271, pp. 7351−7356.
- MacDonald A., Holden C., Harris G. Nutritional strategies in cystic fibrosis: current issues. J R Soc Med. 1991. — Vol.84. — Suppl. N18. — P.28−35.
- McCarty M. Purification and properties of deoxyribonuclease isolated from beef pancreas. Jornal of General Physiology 1946- 29: 123−139.
- McMinn R.M.H., Kugler J.H. The glands of the bile and pancreaticducts: autoradiografic and histochemical studies. // J. Anat. 1961. — V.95. -P.5−11.
- Menzin J, Oster G, Devies L. Et al. A muiltinational economic evaluation of rliDNase in the treatment of cystic fibrosis. Int J Technol Assess Healthcare 1996- 12: 52−61.
- Meyer КС, Lewandoski JR, Zimmerman JJ. et al. Human neutrophil elastase and elastase/ai -antiprotease complex in cystic fibrosis. Rev Resp Dis 1991- 144: 580−5.
- Milla C.E. Long term effects of aerosolized rliDNase on pulmonary disease progression in patients with cystic fibrosis. Thorax, 1998, Vol. 53, pp. 1014- 1017.
- Moore В., Durie P., Forstner G., Pencharz P. The assessment of nutritional status in children. // Nutri. Res. 1985. — Vol.57 — P.97−99.
- Moore K.W., O’Garra A., de Waal Malefyt R., Vieira P., Mosmann T.R. Interleukine-10. Annu. Rev. Immunol., 1993, Vol. 11, pp. 165−190.
- Moss R.B., Bocian R.C., Hsu Y.P., Dong Y.J., Kemna M., Wei Т., Gardner P. Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin. Exp. Immunol., 1996, Vol. 106(2), pp. 374−388.
- Osborne L.R., Lynch M., Middleton PG., Alton EW., Geddes DM., Pryor JP., Hodson ME., Santis GK. Nasal epithelial ion transport an genetic analysis in infertile men with congenital absence of the vas deferens. Hum Mol Genet 2: 1605−1609,1993
- Oster G, Huse DM, Lacey MJ, Regan MM, Fufs HJ. Effects of recombinant human DNase therapy on health care use and cost in patients with cystic fibrosis. Ann Pharmacother 1995- 29: 459−64.
- Picot R, Das I, Reid L. Pus desoxyribonucleic acid and sputumviscosity. Thorax 1978- 33: 235−42.
- Potter J, Matthews LW, Lemm J, Spector JS. Composition of pulmonary secretios from patients with and without cystic fibrosis. Am J. Dis Child 1960- 199: 493−495.
- Puchelle E, Zahm JM, Bentzmann S. Et all. Effects of rhDNase on purulent airway secretions in chronic bronchitis. Europ.resp.J 1996, Vol 9, N4, p 756−769.
- Pukhalsly A.L., Shmarina G.V., Kapranov N.I., Kokarovtseva S.N., Pukhalskaya D.A., Kashirskaja N.J. Anti-nflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Med. Inflam. 2004, 17(2): 111−117.
- Ramsey B.W., Astley S.J., Aitken M.L. et al. Efficacy and safety of short-term administraion of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. // Am. Rev. Respir. Dis. -1993.-V.148.-P.145−151.
- Ranasinha C, Assoufi B, Shak S et al Effecacy and safety of short-term administration of aerosolised recombinant human DNase in adult whit stable stage cystic fibrosis. Lancet 1993- 342: 199−202.
- Regnis J.A., Robinson M., Baileu D.L. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am. J. Respir. Crit. Care Med., 1994, Vol. 150, pp. 66−71.
- Rich D.P., Gregory R.J., Anderson M.P., Manavalan P., Smith A.E., Wrlsh M.J. Effect of deliting the R domain on CFTR-generated chloridechannels. Science, 1991, Vol. 253, pp. 205−207.
- Richman-Eisenstat J.B., Jorens P.G., Hebert C.A., Ieki I., Nadel J.A. Inter-leukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am. J. Physiol., 1993, Vol. 26, pp. L413-L418.
- Riordan JR, Rommens JM, KeremB et al. Identification of the cystic fibrosis gene: Cloning and characterisation of complementari DNA. Science 1989- 245: 1066−1073.
- Rochat T, Dayer Pastore F, Schlegel-Haueter SE, Filthuth I, Auckenthaler R, Belli D, Suter S. Aerosoiled rliDNase in cystic fibrosis: effect on leukocyte proteases in sputum. Eur Respir J 1996- 9: 2200−2206.
- Rosenstein BJ, Johnson CAC et al. Long-term follow-up of Phase III rliDNase trial. Pediatric Pulmonology 1994- Suppl 10: 113−114.
- Ruef C., Jefferson D.M., Schlegel-Hauter S.E., Sueter S. Regulation of cyto-kine secretion by cystic fibrosis airway epithelial cells. Eur. Respir. J., 1993, Vol. 6, pp.1429−1436.
- Schwartz R.H., Milner M.R. Other manifestations and organinvolvment. // In: Cystic fibrosis. Taussig L.N. ed. Thieme-Stratton, Inc., New York, 1984.
- Shah PL, Bush A, Canny GJ et al. Recombinant human Dnase 1 (rliDNase) in cystic fibrosis patients whit severe pulmonary disease: short-term, double-blind stady followed by a six month open-label triatment. // Eur Respir J 1995- 8: 954−958.
- Shah PL, Convey SP, Scott SF, Rainisio M, Wildman M, Stableforth D, Hodson ME. A case-controlled stady with Dornase Alfa to evaluate impact on disease progression over a 4-year period. // Respiration 2001- 68
- Shah PL, Scott SF, Hodson ME. Lobar atelectasis in cystic fibrosis and treatmen witht recombinant human Dnasel. Resp.Med., 1994, Vol 88, N4, p.313−315.
- Shah PL, Scott SF, Knight RA, Hodson ME. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. Eur Respir J 1996- 9:531−534.
- Shak S, Capon D J, Hellniss R, et al. Recombinant human Dnase 1 reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990- 87:9188−92.
- Sheils С A, Kas J, Travasson WH. Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease. Am J. Pathol. 1996, Vol 148, N 3, p.919−927.
- Sinha S» Watorek W., Karr S., Giles J., Bode W., Travis J. Primary structure of human neutrophil elastase. Proc. Natl. Acad. Sci. USA, 1987, Vol. 84, pp. 2228−2232.
- Smith AE. Cationic lipid mediated gene transfer to the lung. Pediatr Pulmonol. 1997−14(suppl), S2.2:82.
- Smith J.J., Travis S.M., Greenberg E.P., Welsh M.J. Cystic fibrosis airway epithelial fail to kill bacteria because of abnormal airway surface fluid. Cell, 1996, Vol.85, pp.229−236.
- Strandvik B. Antibiotic therapy of pulmonary infections in cystic fibrosis.-1988.-S.146−149.
- Stutts M.J., Rossier B.C., and Boucher R.C. Cystic fibrosis transmembrane conductance regulator inverts protein kinase-A-mediated regulation of epithelial sodium channel single channel kinetics. J. Biol. Chem., 1997, Vol. 272, pp. 14 037−14 040.
- Stutts MJ, Canessa CM, Olsen JC et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995- 269: 847−50.
- Suter S., Schad J.M., Roux I. Granulocyte neutral proteases and Pseudomo-nas elastase as possible causes of airway damage in patients withcystic fibrosis. J. Infect. Dis., 1984, Vol. 149, pp. 523−531.
- Tanner J.M. Growth as a monitor of nutritional status. Proceeding of the Nutrutional society. 1976. N.35. — 315−322.
- Taussig L.M., Kattwinkel J., Friedewald W.T., Di Sant’Agnese P.A. A new prognostic score and clinical evalution system for cystic fibrosis.// J. Pediatr. 1973. — Vol.82.-P.380−90
- Travis J. Structure, function, and control of neutrophil proteinases. -Am. J. Med., 1988, Vol. 84, pp. 37S-41S.
- Tummler B. Unusual mechanism of pathogenicity of Pseudomonas aeruginosa isolates from patients with cystic fibrosis // Infection. 1987. -Jul-Aug- 15(4): 311−2.
- Wallace CS, Hall M, Kuhn RJ. Therapy review: pharmacologic management of cistic fibrosis. Clin Pharm. 1993−12:657−701.
- Waterlow J.C., Buzina R., Keller W., Lane J. N, et al. The presentation and use of height and weight data for comparing the nutritional status of groups of children under the age of 10 years. Bulletin of the WHO Organisation. 1977. — N.55. — P.489−498.
- Weiss S.J. Tissue destruction by neutrophils. // N. Engl. J. Med., 1989,1. Vol. 320, pp. 365−376.
- Welsh MJ, Tsui L-C, Boat TF, Reaudet AL. Cystic fibrosis. In Servier CR., Reaudet ALSly WS, Valle D eds. The metabolic and molecular basis of inherited disease. 7 th ed. Vol. 3. New York McGraw-Hill, 1995: 3799−876.
- Williams MT. Chest physiotherapy and cystic fibrosis. Chest 1994- 106: 1872−82.
- Wills PJ, Wodehouse t, Corkey et al. Short-term recombinant human Dnase in bronchiectasis. Effect on clinical stste and in vitro sputum transportability. Am. J.Resp.Critical Care med, 1996, Vol 154, p 413−417.
- Wilson J. Adenovirus Vectors FOR Gene Therapy for CF. Pediatr Pulmonol. 1997−14(suppl), S2.1:80−81.
- Wine J.J. The genesis of cystic fibrosis lung disease. The J. of clinical Inv., 1999, Vol. 103, pp. 309−312.
- Yankaskas J.R. Human submucosal gland and bronchiolar secretions. Abstracts of Current NIH Support Research Grants in CF. 1998 — Project Number: 5 R 01 HL 58 343−02.
- Yu H., Nasr S.Z., and Deretic V. Innate Lung Defenses and Compromised Pseudomonas aeruginosa Clearance in the Malnourished Mouse Model of Respiratory Infections in Cystic Fibrosis. Infection and Immunity, 2000, Vol. 68, № 4, pp. 2142−2147.
- Zeitlin PL. Presented an the Tenth Annual North American Cystic Fibrosis Conference-October 24−27,1996- Orlando, Florida.1. Xl52